Home    About NDEI   Site Map   FAQ   Contact Us   Feedback   
       Advanced Search    
Home
Slide Library
Literature Alerts
On Demand Activities
Case Studies
Newsletters
Live Events
Treatment Guidelines
Patient Education
Clinical Trials
Product Indications
Calendar Of Events
Glossary
Other Resources
CME Opportunities


Your Online Resource for Diabetes Treatment
Home > Literature Alerts > Recent Articles
Updated June, 08 2009

Recent Diabetes Articles


Add to Google
Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L
Diabetes Care. 2009 Jun 5. [Epub ahead of print]
Risk of type 2 diabetes among individuals with high and low glomerular filtration rates
Lorenzo C, Nath SD, Hanley AJ, Abboud HE, Gelfond JA, Haffner SM
Diabetologia. 2009;52(7):1290-1297
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
The BARI 2D Study Group
N Engl J Med. 2009 Jun 7. [Epub ahead of print]
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Home PD, Pocock SJ, Beck-Nielsen H, et al, for the RECORD Study Team
Lancet. 2009 Jun 5. [Epub ahead of print]
Hypoglycemia unawareness in older compared to middle-aged patients with type 2 diabetes
Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B
Diabetes Care. 2009 Jun 1. [Epub ahead of print]
The pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia
Pruski M, Krysiak R, Okopien B
Diabetes Care. 2009 May 12. [Epub ahead of print]
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus
Rosenstock J, Niggli M, Maldonado-Lutomirsky M
Diabetes, Obesity and Metabolism. 2009 Mar 28. [Epub ahead of print]
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
Bosi E, Dotta F, Jia Y, Goodman M
Diabetes, Obesity and Metabolism. 2009;11(5):506-515
Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus
Gimeno-Orna JA, Faure-Nogueras E, Castro-Alonso FJ, Boned-Juliani B
Am J Cardiol.. 2009;103(10):1364-1367
Poor glycemic control is an independent risk factor for low HDL-C in patients with type 2 diabetes
Gatti A, Maranghi M, Bacci S, et al
Diabetes Care. 2009 Jun 1. [Epub ahead of print]
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
Bellamy L, Casas JP, Hingorani AD, Williams D
Lancet. 2009;373(9677):1773-1779
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Rajamani K, Colman PG, Li LP, et al for the FIELD study investigators
Lancet. 2009;373(9677):1780-1788
Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD)
McEwen LN, Bilik D, Johnson SL, et al
ACC Abstracts of the 48th Scientific Session. 2009;32(6):971-976
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide
Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA
ACC Abstracts of the 48th Scientific Session. 2009;32(5):409-418
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Ray KK, Seshasai SR, Wijesuriya S, et al
Lancet. 2009;373(9677):1765-1772
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction
Goyal A, Mehta SR, Gerstein HC, et al
Am Heart J. 2009;157(4):763-770
Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2)
Ramachandran A, Snehalatha C, Mary S, et al
Diabetologia. 2009;52(6):1019-1026
Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men
Stancáková A, Javorský M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M
Diabetes. 2009;58(5):1212-1221
Elevated A1C in adults without a history of diabetes in the US
Selvin E, Zhu H, Brancati FL
Diabetes Care. 2009;32(5):828-833
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
Dore DD, Seeger JD, Arnold Chan K
Curr Med Res Opin. 2009;25(4):1019-1027
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial
Bunck MC, Diamant M, Cornér A, et al
Diabetes Care. 2009;32(5):762-768
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes: An Overview of Data from PROactive
Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; on behalf of the PROactive investigators
Drug Saf. 2009;32(3):187-202
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Tahrani AA, Piya MK, Barnett AH
Adv Ther. 2009;26(3):249-262
Impact of sitagliptin on markers of beta-cell function: a meta-analysis
Riche DM, East HE, Riche KD
Am J Med Sci. 2009;337(5):321-328
Risk Management and Outcomes of Adverse Events to Pioglitazone in Primary Care in the UK: An Observational Study
Fogg C, Kasliwal R, Shakir SA.
Drug Saf. 2009;32(3):229-237.
 

Clinical Bridges, Secaucus, NJ
Clinical Bridges is a division of KnowledgePoint360 Group, LLC.
Copyright © 2009 Clinical Bridges. All rights reserved.
National Diabetes Education Initiative, Clinical Bridges, and
KnowledgePoint360 are trademarks of KnowledgePoint360 Group, LLC.
Disclaimer Statement - Privacy Statement